Venus Remedies has secured its first patent from Canada for its novel antibiotic adjuvant entity ‘Vancoplus’. The patent, granted by the Canadian patent office, is valid up to May 2027. The company is planning to launch the product in Canada in the next two years.
Dr Manu Chaudhary, JMD, Director- Research says, “We are really enthusiastic over the receival of this Canadian patent for Vancoplus, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus aureus (MRSA) infection rates in Canada.” Dr Chaudhary further added, “Vancoplus seems to be the only effective and safe option to curb the notorious MRSA strain. As the Canadian pharma market is the third fastest growing market globally, it shows the great growth potential for R&D players in the industry to create better drugs to curb such diseases. With this patent, we are hopeful of capturing a significant share in the Canadian pharma market.”
Dr Mufti Suhail Sayeed, Sr Vice President, Venus Medicine Research Centre (VMRC) stated, “Vancoplus is an ‘Antibiotic Adjuvant Entity’ (AAE) constituting Ceftriaxone plus Vancomycin along with an adjuvant which restricts the production of toxin by MRSA pathogens and is highly effective in combating MRSA along with other advantages of reduced treatment time, cost and adverse effects.”
The company is marketing Vancoplus successfully in India and emerging markets across the globe. Venus Remedies’ Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian regulatory authorities to market the drug. Apart from Canada, the patent for this product has already been granted from the US, South Africa, New Zealand and Ukraine and Australia authorities.
